24/7 Market News Snapshot 03 June, 2025 – I-MAB American Depositary Shares (NASDAQ:IMAB)

June 3, 2025

DENVER, Colo., 03 June, 2025 (www.247marketnews.com) – (NASDAQ:IMAB) are discussed in this article.
I-MAB has experienced a significant surge in its American Depositary Shares, with the stock opening at $1.28 and climbing to a current trading price of $1.665, marking a remarkable increase of 30.08%. This surge comes on the heels of increased investor interest, as reflected in a robust trading volume of 1.14 million shares. This upward momentum signals a pivotal opportunity for I-MAB, attracting attention from both seasoned investors and newcomers in the market.

In addition to this impressive market performance, I-MAB is poised to highlight its advancements in cancer treatment at the upcoming H.C. Wainwright “HCW@Home” Series on June 17, 2025. The virtual event will focus on the therapeutic potential of Claudin 18.2 in gastric cancers and will feature discussions on I-MAB’s innovative bispecific antibody, givastomig. Led by CEO Sean Fu, PhD, and CMO Phillip Dennis, MD, PhD, the session will explore how givastomig leverages the 4-1BB signaling pathway to reactivate T cells within the tumor microenvironment.

Moreover, critical findings from a pivotal Phase 1 dose escalation study of givastomig, in conjunction with immunochemotherapy, will be showcased in a Mini Oral presentation at the ESMO GI Cancers Congress on July 2, 2025. This study underscores givastomig’s potential as a leading candidate for the treatment of Claudin 18.2-positive gastric cancers, demonstrating significant anti-tumor efficacy while mitigating common treatment-related toxicities.

As I-MAB continues its commitment to innovation within the oncology landscape, the company ensures that stakeholders will have access to this vital information and will broadcast a webcast of the upcoming event for 90 days, promoting transparency in its research endeavors.

Related news for (IMAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.